Addyi and Finasteride Interaction: What Every Woman Should Know

What Is the Interaction Between Addyi and Finasteride?

No dedicated pharmacokinetic study has examined flibanserin and finasteride together in women. What clinicians currently understand comes from the mechanism of each drug, their metabolic pathways, and the known physiology of androgen-driven sexual desire in women. The interaction is best described as pharmacodynamic rather than a classical enzyme-level drug-drug interaction, though there is a shared metabolic route that deserves attention.

Flibanserin (Addyi) works centrally. It is a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, with additional dopamine D4 agonist activity. This combination is thought to rebalance excitatory and inhibitory neurotransmitters in the prefrontal cortex that govern sexual desire, shifting the ratio toward more dopamine and norepinephrine and less serotonin in that circuit.

Finasteride blocks type II and, at higher doses, type I 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). In women, androgens, including testosterone and DHT, contribute to genital arousal and sexual motivation. A 2019 systematic review in the Journal of Sexual Medicine found that androgen levels, particularly free testosterone, correlate positively with sexual desire scores in premenopausal women, though the relationship is not linear or simple.

When you lower DHT pharmacologically while simultaneously trying to boost dopaminergic tone to improve desire, you are working against yourself at the substrate level. The clinical significance of that is not quantified in any published trial, but the biological logic is clear.

The CYP3A4 Overlap

Flibanserin is primarily metabolized by CYP3A4, with minor contributions from CYP2C19. Finasteride is also substantially cleared by CYP3A4. When two drugs share the same primary metabolic enzyme, competition for that enzyme can raise plasma concentrations of one or both drugs. The FDA Addyi label lists strong CYP3A4 inhibitors as contraindicated and moderate inhibitors as requiring careful risk assessment.

Finasteride is not a CYP3A4 inhibitor. It is a substrate. Competition between two substrates for the same enzyme generally produces modest and clinically variable effects compared with the substrate-inhibitor scenario. Still, in women who already have slower CYP3A4 activity (estrogen status affects CYP3A4 induction; postmenopausal women may metabolize CYP3A4 substrates differently than premenopausal women), this substrate competition could be more meaningful.

Pharmacodynamic Concern: Androgen Pathway Antagonism

This is the more clinically pressing issue. Sexual desire in women depends on a balance of androgens, estrogens, and central neurotransmitters. Finasteride, by reducing DHT, reduces one of the key peripheral and central androgenic signals that feed into sexual motivation circuitry.

A 2004 prospective study in the Journal of the American Academy of Dermatology reported that 36% of women taking oral finasteride 2.5 mg daily for female pattern hair loss experienced decreased libido as an adverse effect. If you are already experiencing hypoactive sexual desire disorder (HSDD) and you take finasteride, you may be adding a pharmacological suppressor of desire on top of an existing deficit. Adding flibanserin to try to correct that deficit while finasteride continues to suppress androgenic signaling is, at minimum, working against the drug's mechanism.

Who Takes Both Drugs? The Real-World Overlap

Most women taking finasteride are doing so for female pattern hair loss (FPHL) or, less commonly, as part of treatment for hyperandrogenism in PCOS. Women with PCOS are also at increased risk for HSDD, partly because of psychological burden and partly because of hormonal dysregulation.

Female Pattern Hair Loss and HSDD

FPHL affects roughly 50% of women by age 50 according to the American Academy of Dermatology. Many dermatologists prescribe finasteride 1 mg to 5 mg daily off-label for FPHL in women, though only minoxidil holds FDA approval for this indication in women. Hair loss itself is associated with psychological distress and reduced sexual self-confidence, which can independently contribute to HSDD.

PCOS and Libido

PCOS affects 6% to 12% of reproductive-age women in the United States, making it the most common endocrine disorder in that group. Women with PCOS who have high androgens might seem to have protected libido from the androgen perspective, but clinical reality is mixed. Finasteride is sometimes used to manage hirsutism in PCOS; simultaneously, studies report HSDD rates in PCOS that are higher than in age-matched controls, driven by body image, irregular cycles, and insulin resistance.

A practical clinical framework for women who ask about this combination:

| Clinical Scenario | Interaction Risk | Suggested Approach | |---|---|---| | FPHL + HSDD, premenopausal, not trying to conceive | Moderate pharmacodynamic antagonism | Discuss finasteride discontinuation or switch to minoxidil before starting flibanserin; reassess desire at 3 months | | PCOS + hirsutism + HSDD, premenopausal | Moderate to high; androgen suppression may worsen baseline desire deficit | Consider spironolactone over finasteride (different mechanism, some data on libido neutrality); address HSDD separately | | Postmenopausal, FPHL + sexual dysfunction | Flibanserin not approved for this population | Pursue menopause-indicated therapies for sexual dysfunction (ospemifene, local estrogen, testosterone where evidence-based) | | Trying to conceive + FPHL + low desire | Finasteride absolutely contraindicated; Addyi not studied in pregnancy | Stop finasteride immediately; evaluate desire with validated tools; treat contributory causes |

Severity Rating and Clinical Classification of This Interaction

Standard drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not currently list flibanserin-finasteride as a named interaction pair with a formal severity rating, because no prospective study exists and neither drug is classically the other's inhibitor or inducer.

Applying the FDA Adverse Event Reporting System framework and mechanism-based reasoning, a reasonable clinical classification would be:

• Pharmacokinetic component: Minor to moderate (shared CYP3A4 substrate competition; not a direct inhibitor interaction).
• Pharmacodynamic component: Moderate (finasteride may blunt the peripheral and central androgenic substrate that supports the dopaminergic rebalancing flibanserin attempts to achieve).
• Overall interaction severity: Moderate, requiring individualized assessment rather than automatic contraindication.

The FDA Addyi prescribing information specifically states that the drug's clinical benefit was demonstrated in women with low sexual desire not accounted for by a co-existing medical or psychiatric condition or relationship problem. A drug that pharmacologically suppresses libido counts as a co-existing medical condition in this framework, which means if finasteride is causing or worsening your HSDD, Addyi may never perform to its labeled potential until that suppressor is removed.

Flibanserin Pharmacology: What Women Need to Know

How Addyi Works in the Female Brain

Flibanserin's mechanism is specific to the premenopausal female brain as studied. The three key Phase 3 trials (DAISY, VIOLET, and BEGONIA) enrolled only premenopausal women and demonstrated that flibanserin increased satisfying sexual events by approximately 0.5 to 1 additional event per month compared with placebo, with statistically significant improvements in desire scores on the Female Sexual Function Index. That effect size is modest but meaningful to women who experience HSDD.

Dose and Administration

The approved dose is 100 mg orally once daily at bedtime. Bedtime dosing is mandatory because CNS depression, including sedation and dizziness, is the primary acute side effect. Taking it at bedtime minimizes functional impairment. Women should not take it during waking hours.

The Alcohol Contraindication

Alcohol is contraindicated with flibanserin. The FDA required a Risk Evaluation and Mitigation Strategy (REMS) program for Addyi specifically because of the severe hypotension and syncope risk when combined with alcohol. This is not a "limit your drinking" advisory. It is a "do not drink alcohol while on this drug" directive. Every woman starting flibanserin should hear this clearly.

CYP3A4 Inhibitors: The Genuine Contraindications

The clinically documented dangerous interactions with flibanserin involve CYP3A4 inhibitors, not substrates like finasteride. Strong CYP3A4 inhibitors such as fluconazole, ketoconazole, itraconazole, clarithromycin, and certain HIV antiretrovirals are contraindicated with flibanserin because they can raise flibanserin plasma levels by 4- to 7-fold, dramatically increasing hypotension and syncope risk. Moderate CYP3A4 inhibitors (fluoxetine, diltiazem, grapefruit) require a 2-week washout or careful risk-benefit discussion. Women prescribed any antifungal, certain antibiotics, or grapefruit-containing supplements need explicit counseling on this.

Finasteride in Women: Sex-Specific Pharmacology

How Finasteride Affects Female Hormones

Finasteride reduces circulating DHT in women as effectively as in men, with 1 mg daily reducing serum DHT by approximately 68% in women, comparable to the 65-70% reduction seen in men at the same dose. However, the baseline DHT level in women is already substantially lower than in men, which means the absolute decrease in androgen exposure is much smaller.

In women with PCOS who have elevated baseline androgens, the relative reduction is the same but the absolute reduction in DHT is larger, and this is precisely where finasteride's libido-suppressing effect may be most clinically relevant. Women who depend on relatively higher androgen levels for sexual desire, which is most apparent in the periovulatory phase of the menstrual cycle, may experience meaningful desire suppression.

Menstrual Cycle Effects

Androgen levels in women peak at midcycle, corresponding to the LH surge, which is also when sexual desire is physiologically at its highest in ovulatory women. Finasteride blunts DHT across the entire cycle, which may disproportionately flatten the midcycle desire peak. This has not been studied directly, but the mechanism supports clinical observation that some women notice a loss of the periovulatory increase in libido while on finasteride.

Pregnancy, Lactation, and Contraception: Required Reading

Finasteride in Pregnancy: Category X, No Exceptions

Finasteride is FDA Pregnancy Category X. It is teratogenic to male fetuses. Animal data demonstrate that finasteride exposure during the critical period of genitourinary development causes feminization of male external genitalia. Although human data are limited to case reports and occupational exposure studies, the mechanism is well established and the risk is considered real.

Any woman of reproductive age taking finasteride must use reliable contraception. This is not optional. If you are trying to conceive, finasteride must be stopped before attempting pregnancy. There is no established safe duration after stopping finasteride before conception, but the drug's half-life is 5 to 6 hours in women, and it is undetectable in serum within 24 hours after the last dose. Most clinicians advise stopping finasteride at least one full menstrual cycle before attempting conception.

Flibanserin in Pregnancy: No Human Data

Flibanserin carries no FDA pregnancy category under the current labeling system (post-2015 PLLR format), and the label states there are no adequate and well-controlled studies in pregnant women. Animal reproduction studies showed adverse effects at doses higher than the human therapeutic dose. The drug is indicated only for premenopausal women, a population with pregnancy potential, making this gap particularly important.

If you discover a pregnancy while taking flibanserin, stop the drug and contact your clinician. There is no data to suggest it is safe to continue, and the labeled indication (HSDD) is not a life-threatening condition that would justify continuation under uncertainty.

Lactation: Both Drugs Are Problematic

Neither finasteride nor flibanserin has established safety data in breastfeeding women. Finasteride has been detected in animal milk, and given its hormonal mechanism, potential effects on a nursing infant, particularly a male infant, are a theoretical concern. Flibanserin's CNS-active mechanism and the complete absence of human lactation data make prescribing it during breastfeeding inadvisable. Women in the postpartum and lactation period should discuss alternative strategies for low desire, including psychotherapy, relationship counseling, and addressing treatable contributors like thyroid dysfunction and postpartum depression, before reaching for either drug.

Contraception Requirements Summary

• Finasteride: reliable contraception required throughout use; stop at least one cycle before trying to conceive.
• Flibanserin: no formal contraception requirement on the label, but given the lack of safety data, use in women who may become pregnant requires a frank discussion.
• Both drugs together: the finasteride contraception requirement covers the combination. Reliable contraception is mandatory.

Who This Combination Is Right For, and Who It Is Not

Women Who Should Not Take Both Drugs Simultaneously

• Anyone currently trying to conceive or who may become pregnant in the near term.
• Women in the postmenopausal stage (flibanserin is not approved for this group).
• Women whose HSDD may be substantially caused or worsened by finasteride (evaluate by trialing a finasteride holiday first).
• Women with hepatic impairment (flibanserin is contraindicated in hepatic impairment; finasteride is also hepatically metabolized).

Women Who Might Reasonably Use Both With Careful Monitoring

• A premenopausal woman with FPHL where finasteride provides clear benefit, who has had HSDD predating finasteride use, uses reliable contraception, does not drink alcohol, and has had a thorough discussion with her prescriber about the pharmacodynamic antagonism and realistic expectations.
• A woman with PCOS who has completed her desired family and now manages both hair loss and persistent HSDD, with monitoring of sexual function scores (Female Sexual Function Index) at baseline and 3 months.

Monitoring should include a validated HSDD assessment tool, such as the Female Sexual Distress Scale-Revised (FSDS-R), at baseline, 4 weeks, and 8 weeks after starting flibanserin. If scores do not improve, the pharmacodynamic antagonism from finasteride is likely a contributing factor, and the risk-benefit of continuing finasteride should be re-evaluated.

Counseling Points for the Clinical Visit

When you discuss this combination with your prescriber, these are the questions worth raising:

1. Has my HSDD been evaluated with a validated tool (FSDS-R or FSFI) before and after starting finasteride, to establish whether finasteride is causally contributing?
2. Could minoxidil (topical) replace finasteride for my hair loss, removing the androgen suppression issue entirely?
3. Am I on any CYP3A4 inhibitors (antifungals, certain antidepressants, grapefruit) that would pose a greater risk with flibanserin than finasteride does?
4. Have thyroid function, iron stores, and depression been ruled out as contributors to low desire before adding a second drug?
5. What is my contraception plan, and is it reliable enough to satisfy the finasteride safety requirement?

ACOG Practice Bulletin guidelines on female sexual dysfunction recommend addressing treatable medical and psychological contributors before initiating pharmacotherapy. Starting flibanserin while a pharmacological libido suppressor (finasteride) remains active contradicts that principle.

What the Evidence Gap Means for You

Women have been significantly under-represented in drug interaction research. The FDA approval trials for flibanserin enrolled approximately 11,000 women total across the development program, which sounds substantial, but co-administration with 5-alpha-reductase inhibitors was not studied, and no subgroup analysis for women concurrently using anti-androgenic drugs exists in the published literature.

This is not a reassurance. It is an honest description of the data. The clinical guidance provided here, and by your clinician, is based on mechanism, pharmacokinetic principles, and clinical judgment. Women who take both drugs are, in a practical sense, ahead of the evidence. That does not mean the combination is automatically unsafe. It means the risk is not quantified and the benefit may be diminished by the pharmacodynamic antagonism.

Asking your clinician to document the reasoning in your chart, and to establish a monitoring plan with explicit stopping criteria, is a reasonable request.